Lungs News and Research

RSS

Curis announces preliminary results of GDC-0449 Phase II clinical trial in advanced ovarian cancer

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has received preliminary results from a Phase II clinical trial of GDC-0449 from Roche and Genentech, Curis' collaborator and a member of the Roche Group.

9 Aug 2010

ESMO Congress provides forum for presentation of new research on treatment of cancer

Cancer is a leading cause of mortality worldwide, accounting for more than one in ten deaths. By 2030, the global burden is expected to exceed 12 million.

9 Aug 2010

Allergy shots can cause systemic side effects: Study

Allergy shots can reduce symptoms of asthma, use of inhaled medications and allergy-related asthma attacks, confirms an updated review of studies. Yet, the treatment can also cause systemic side effects that range from a stuffy nose to fatal anaphylactic shock.About 30 percent of asthma patients experience improved breathing after receiving a series of injections that desensitize their immune systems to specific irritants, according to the review. The medical term for this treatment protocol is allergen immunotherapy.

9 Aug 2010

Cyclacel second-quarter net loss decreases to $6.5 million

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported its financial results and business highlights for the second quarter of 2010.

7 Aug 2010

Response Genetics total revenue for second-quarter 2010 increases 197% to $5.6 million

Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced its consolidated financial results for the three and six months ended June 30, 2010.

7 Aug 2010

TrueBeam technology reduces cancer radiation treatment time

The Department of Radiation Oncology at the University of Alabama at Birmingham Comprehensive Cancer Center is among the world's first to begin using radiation technology that dramatically reduces treatment times.UAB's Hazelrig-Salter Radiation Oncology Center is the third U.S. site to acquire TrueBeam technology. TrueBeam, by Varian Medical Systems Inc., can complete a standard 40-minute radiation therapy in less than a minute for select patients. The precision of the instrument, measured in increments of less than a millimeter, comes from real-time patient imaging, positioning, beam shaping and many other data points synchronized continually as treatment progresses.

7 Aug 2010

Multiple tattoos increase risk of contracting hepatitis C: Study

Youth, prison inmates and individuals with multiple tattoos that cover large parts of their bodies are at higher risk of contracting hepatitis C and other blood-borne diseases, according to a University of British Columbia study.The researchers reviewed and analysed 124 studies from 30 countries, including Canada, Iran, Italy, Brazil and the United States, and found the incidence of hepatitis C after tattooing is directly linked with the number of tattoos an individual receives. The findings are published in the current issue of the International Journal of Infectious Diseases.

7 Aug 2010

OncoGenex reports net income in second-quarter 2010 against loss last year

OncoGenex Pharmaceuticals, Inc. today reported unaudited financial results for the three and six months ended June 30, 2010 and reviewed the Company's highlights for the second quarter of 2010.

7 Aug 2010

BCF publishes two new patient publications

The Bone and Cancer Foundation is announcing the publishing of two new patient publications on Pain Management and Physical Therapy and other Rehabilitation Therapies. Other publication topics include: Breast Cancer, Prostate Cancer, Lung Cancer, Osteonecrosis of the Jaw, Vitamin D, Surgery, Myeloma and Osteosarcoma.

7 Aug 2010

Helmsley Charitable Trust awards $3.15M grant to support UofL James Graham Brown Cancer Center

The University of Louisville has received a $3.15 million grant from the Leona M. and Harry B. Helmsley Charitable Trust to support the UofL James Graham Brown Cancer Center and cancer research taking place in Owensboro. The grant will be matched with state "Bucks for Brains" funding to bring more than $4.5 million to the Owensboro Cancer Research Program.

6 Aug 2010

Sanofi-aventis receives FDA approval for new Taxotere Injection Concentrate formulation

Sanofi-aventis U.S. announced today that the U.S. Food and Drug Administration (FDA) has approved a new one-vial formulation of its chemotherapeutic agent Taxotere® (docetaxel) Injection Concentrate. The 1-vial Taxotere is anticipated to become available to cancer treatment clinics and hospitals nationwide in the fall in both 80 mg and 20 mg dosages.

5 Aug 2010

Life Technologies, UCSD Moores Cancer Center to use SOLiD 4 technology to study CLL

Life Technologies Corporation and the University of California at San Diego Moores Cancer Center today announced a partnership to use SOLiD 4 genomic analysis technology in a research program to study chronic lymphocytic leukemia, a cancer of the white blood cells. The CLL research is made possible by funding from the National Institutes of Health and will enable scientists to survey the whole transcriptomes of 96 CLL tumor samples for potential biomarkers.

5 Aug 2010

Inspire second-quarter total revenue increases 18% to $27.3 million

Inspire Pharmaceuticals, Inc. announced today financial results for the second quarter ended June 30, 2010, reporting a net loss of $8.8 million or ($0.11) per share, an improvement from the second quarter of 2009 during which the Company incurred a net loss of $9.5 million or ($0.17) per share.

5 Aug 2010

PFF announces introduction of Pulmonary Fibrosis Research Enhancement Act in US Senate

The Pulmonary Fibrosis Foundation (PFF) today announced that the Pulmonary Fibrosis Research Enhancement Act (PFREA) was introduced in the United States Senate. The PFREA was introduced by Senators Patty Murray (D-WA) and Mike Crapo (R-ID), and the PFF has offered its unconditional endorsement to pass this important legislation on behalf of the pulmonary fibrosis community.

5 Aug 2010

Penn. effort fades to override cuts to family planning; Ill. faces budget cuts to health care; Mich. focuses on high cost of chronic disease

The Philadelphia Inquirer: "As two Democratic state lawmakers initiated a campaign to override the governor's veto of $7.5 million for family-planning health centers, six Republican state senators who previously voted to restore the funding reversed course, most likely ending any hopes of restoring the money. Democrats would need at least four Republican votes for an override in the Senate, which now appears unlikely.

5 Aug 2010

Scientists analyze new technique to quickly identify particular asthma subtypes

For many people afflicted by asthma, treatment can be a frustrating and time-consuming experience. After their initial diagnosis, asthmatics find themselves caught in a trial and error process that can last for months, as doctors gradually escalate their medications to treat their condition effectively with minimal side effects. And until the right medicine and dosage are found, patients continue to suffer attacks that strike without warning and can leave them struggling for breath for hours or even days.

5 Aug 2010

Alnylam second-quarter revenues increase to $26.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2010, and company highlights.

5 Aug 2010

ImmunoGen fourth-quarter 2010 net loss increases to $13.4 million

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced financial results for the three-month period and fiscal year ended June 30, 2010.

5 Aug 2010

Sigma-Aldrich, NHLBI and BU collaborate in atherosclerotic cardiovascular disease research

Sigma-Aldrich® today announced it has entered into an agreement with the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, and Boston University (BU) to develop methods to measure several potential biomarkers of atherosclerotic cardiovascular disease (CVD) using plasma samples from the NHLBI's Framingham Heart Study (FHS), one of the most prestigious clinical studies in medicine. Funding for the project is provided by the NHLBI to Sigma-Aldrich under a research subaward agreement with BU.

5 Aug 2010

Scientists invent Global Focus microscope for tuberculosis diagnosis

A compact microscope invented at Rice University is proving its potential to impact global health. In a paper published online today in the journal PLoS ONE, Rice alumnus Andrew Miller and co-authors show that his portable, battery-operated fluorescence microscope, which costs $240, stacks up nicely against devices that retail for as much as $40,000 in diagnosing signs of tuberculosis.

5 Aug 2010

Lungs News and Research

Curis announces preliminary results of GDC-0449 Phase II clinical trial in advanced ovarian cancer

ESMO Congress provides forum for presentation of new research on treatment of cancer

Allergy shots can cause systemic side effects: Study

Cyclacel second-quarter net loss decreases to $6.5 million

Response Genetics total revenue for second-quarter 2010 increases 197% to $5.6 million

TrueBeam technology reduces cancer radiation treatment time

Multiple tattoos increase risk of contracting hepatitis C: Study

OncoGenex reports net income in second-quarter 2010 against loss last year

BCF publishes two new patient publications

Helmsley Charitable Trust awards $3.15M grant to support UofL James Graham Brown Cancer Center

Sanofi-aventis receives FDA approval for new Taxotere Injection Concentrate formulation

Life Technologies, UCSD Moores Cancer Center to use SOLiD 4 technology to study CLL

Inspire second-quarter total revenue increases 18% to $27.3 million

PFF announces introduction of Pulmonary Fibrosis Research Enhancement Act in US Senate

Penn. effort fades to override cuts to family planning; Ill. faces budget cuts to health care; Mich. focuses on high cost of chronic disease

Scientists analyze new technique to quickly identify particular asthma subtypes

Alnylam second-quarter revenues increase to $26.6 million

ImmunoGen fourth-quarter 2010 net loss increases to $13.4 million

Sigma-Aldrich, NHLBI and BU collaborate in atherosclerotic cardiovascular disease research

Scientists invent Global Focus microscope for tuberculosis diagnosis

The ultimate guide to lung research tools and protocols eBook

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Latest News